Responses cited increasing workloads, shrinking autonomy, mounting interference from hospital administrators and insurance ...

A group of faith leaders, community advocates, and activists continues to call on the Monroe County District Attorney's ...

The following letter was submitted to The Montana Standard from Butte-Silver Bow Chief Executive J.P. Gallagher. Writing on ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with ...

Hidden narcissists often use this phrase to justify their reactions and avoid accountability, subtly making themselves the ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its ...

Naidu’s remarks came after Lourdu Mary, the wife of the deceased Cheeli Singaiah, met YS Jagan Mohan Reddy. The YSRCP later ...

The June 22 attack on the Mar Elias Church in Damascus underscores the threat of extremism in Syria even after the fall of ...

Pfizer said a late-stage study of its Hympavzi hemophilia drug met its key goals in patients with the blood-clotting disorder who have inhibitors that can render some treatments ineffective.

The survey also comes as tensions heat up between Israel and Iran and concerns Israel could launch a strike on Tehran's nuclear plants.

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...